Mulberry fruit extract is a concentrated berry supplement from white and black mulberry trees used for mealtime blood sugar control and inflammation. Administered orally with starch or sugar meals, it blunts after-meal blood sugar and insulin spikes, though all extract trials come from one industry group. Evidence for blood fats, inflammation, blood pressure, and cognition is low and frequently conflicted, with gas emerging mainly at higher intakes. (Full Review)
| Marker | Target | Why |
|---|---|---|
| 2-Hour Postprandial Blood Glucose iAUC | No established target; ≥20% reduction in 2-hour post-meal glucose iAUC from the individual's own baseline | Efficacy marker: primary clinical outcome changed by MFE |
| Fasting Triglycerides | <150 mg/dL (standard reference range) | Efficacy marker: expected to decrease with daily concentrated fruit intake |
| High-Density Lipoprotein Cholesterol (HDL-C) | >40 mg/dL in men, >50 mg/dL in women (standard reference range) | Efficacy marker: expected to increase modestly over 8 weeks |
| High-Sensitivity C-Reactive Protein (hs-CRP) | <3.0 mg/L (standard reference range) | Efficacy marker: expected to decline with 6–8 weeks of supplementation |
| Fasting Blood Glucose | 70–99 mg/dL (standard reference range) | Safety check: screens against hypoglycemia (<70 mg/dL) if stacked with antidiabetic agents |
| Estimated Glomerular Filtration Rate (eGFR) | ≥90 mL/min/1.73 m² (standard reference range) | Safety check: verifies renal capacity to excrete absorbed 1-DNJ |
Cadence: 1–2 week baseline before initiation; postprandial glucose excursions and gastrointestinal tolerance at weeks 1 and 4; fasting venous biomarkers (fasting blood glucose, triglycerides, HDL-C, hs-CRP, eGFR) at baseline, at 6–8 weeks, and every 6 months thereafter during sustained use (eGFR every 6–12 months).